
Opinion|Videos|August 14, 2024
EMA vs Telomerase Inhibitor for RS+ patients after ESA failure
Author(s)Abdulraheem Yacoub, MD
Advertisement
Episodes in this series

- With the advent of new options for treatment after ESAs for patients with LR-MDS, please share your thoughts about the choice between an EMA versus a telomerase inhibitor in the RS positive patient?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















